Effectiveness of Personalized Surveillance and Aftercare for Breast Cancer
Launched by COMPREHENSIVE CANCER CENTRE THE NETHERLANDS · Aug 2, 2023
Trial Information
Current as of November 14, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The NABOR study is observing whether a personalized plan for follow-up care after breast cancer treatment works better than the usual “one-size-fits-all” follow-up. It wants to enroll about 1,040 women who are 40 years or older, have had invasive breast cancer that was treated with curative intent, and are starting their regular follow-up at one of several Dutch hospitals. To join, you must be female, 40 or older, have been treated for non-metastatic breast cancer, and be able to understand Dutch. People with cancer in both breasts, certain gene carriers (BRCA1/2 or CHEK2), those who need MRI as part of their care, or those already in another study with fixed follow-up visits are not eligible.
If your hospital switches to personalized follow-up, you may receive care based on your individual risk and needs (PSP and PAP), or you may continue with the usual follow-up. The study will collect information from you through questionnaires over up to three years and pull data from medical records to track imaging, treatment, visits, and any recurrences. The main question is whether personalized follow-up reduces cancer worry and improves overall quality of life, with many additional measures such as other aspects of quality of life, work and healthcare use, risk perception, decision-making, satisfaction, and social participation. Participation involves signing consent and completing surveys, and results could help tailor survivorship care for breast cancer (and possibly other cancers) in the future.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • female,
- • aged 40 years or older (because of higher risk on recurrence),
- • facing the decision for the organization of post-treatment surveillance and aftercare,
- • being curatively treated including breast surgery, for invasive non-metastasized breast cancer
- • able to understand the Dutch language in speech and writing.
- Exclusion Criteria:
- • bilateral breast cancers,
- • BRCA1/2 or CHEK2 carriers,
- • having an indication for MRI
- • participation in another study that requires fixed scheduled follow-up consultations and/or imaging.
About Comprehensive Cancer Centre The Netherlands
The Comprehensive Cancer Centre the Netherlands (CCCN) is a leading institution dedicated to advancing cancer research, treatment, and patient care through collaborative efforts across various healthcare disciplines. Committed to improving outcomes for cancer patients, CCCN integrates cutting-edge clinical trials, innovative therapies, and comprehensive support services. The center fosters a multidisciplinary approach, bringing together experts in oncology, radiology, pathology, and other fields to enhance the understanding of cancer biology and develop personalized treatment strategies. With a focus on translating research findings into clinical practice, CCCN is at the forefront of cancer care in the Netherlands, striving to provide the highest standard of care and contribute to global advancements in oncology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zwolle, Overijssel, Netherlands
Apeldoorn, Gelderland, Netherlands
Hengelo, Overijssel, Netherlands
Dordrecht, Zuid Holland, Netherlands
Arnhem, Gelderland, Netherlands
Den Bosch, Brabant, Netherlands
Uden, Brabant, Netherlands
Alkmaar, Noord Holland, Netherlands
Den Haag, Zuid Holland, Netherlands
Leiderdorp, Zuid Holland, Netherlands
Patients applied
Trial Officials
Sabine Siesling
Principal Investigator
Comprehensive Cancer Center of The Netherlands
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported